Finerenone reduced cardiovascular and kidney events across CKM stages in adults with diabetes and CKD, supporting broader risk assessment alongside individualized treatment and monitoring.

SGLT inhibitors reduce heart failure hospitalizations across ejection fractions and diabetes status, offering broad cardiovascular benefits while producing more modest reductions in mortality.

WHO introduced standardized terminology for hypertension-control programs, creating shared definitions that improve care pathways, reporting, data alignment, accountability, and cross-system comparisons without changing clinical treatment.

WHO’s July 2026 HIV update revises pediatric antiretroviral weight-band dosing and preferred regimens, emphasizing neonatal prophylaxis, formulation, growth, and prescription review.

FDA approval expands Pluvicto into PSMA-positive metastatic hormone-sensitive prostate cancer, enabling earlier radioligand therapy alongside ARPI treatment before castration resistance.

The FDA ended emergency authorizations for COVID-19 diagnostics and devices, requiring health systems to verify each product’s current regulatory status before continued use.

FDA expanded perioperative enfortumab vedotin plus pembrolizumab to cystectomy-eligible muscle-invasive bladder cancer, regardless of cisplatin eligibility, broadening pre- and postoperative treatment options.

The 2026 guideline integrates lipid care with CKM staging, PREVENT-ASCVD risk assessment, explicit LDL-C goals, optional apoB testing, and one-time Lp(a) measurement.

The 2026 guideline retains 130/80 mm Hg as hypertension’s threshold, while cardiovascular risk determines medication timing, with most treated adults targeting below 130/80 mm Hg.

Perioperative enfortumab vedotin plus pembrolizumab improved survival and complete response rates versus cisplatin chemotherapy in resectable muscle-invasive bladder cancer.